CompletedInterventional · Phase 3NCT02278718 ↗A Multicenter, Multinational, Randomized, Controlled, Open Label Study, Performed in Children With Thermal Burns, to Evaluate the Efficacy and Safety of NexoBrid as Compared to Standard of Care (SOC) Treatment
CompletedInterventional · Phase 3NCT02518594 ↗A Randomized Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short CervixDaniel W SkupskiPIInterventionDrug: Vaginal progesterone · Drug: Placebo · Device: Arabin PessaryDatesNov 2015 – Dec 2024· Results postedSponsorEunice Kennedy Shriver National Institute of Child Health and Human DevelopShort Cervical Length
CompletedInterventional · Phase 3NCT02981407 ↗Myocardial Ischemia and TransfusionXuming DaiPIInterventionBiological: Red Blood Cell TransfusionDatesApr 2017 – May 2023· Results postedSponsorRutgers UniversityMyocardial InfarctionAnemia
CompletedInterventional · Phase 3NCT03149003 ↗A Randomized, Multicenter, Adaptive Phase 3 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD 201G)Howard Alan FinePIInterventionDrug: DSP-7888 Dosing Emulsion · Drug: BevacizumabDatesDec 2017 – Aug 2021· Results postedSponsorBoston Biomedical Inc.Glioblastoma
CompletedInterventional · Phase 3NCT03268954 ↗A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous LeukemiaPinkal DesaiPIInterventionDrug: Azacitidine · Drug: PevonedistatDatesNov 2017 – May 2021· Results postedSponsorTakeda Pharmaceutical Company LimitedMyelodysplastic SyndromeLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
CompletedInterventional · Phase 3NCT03283085 ↗A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)Ellen J ScherlPIInterventionDrug: 25 mg Ontamalimab · Drug: 75 mg OntamalimabDatesFeb 2018 – Dec 2023· Results postedSponsorShire Pharmaceuticals, Inc.Crohn's DiseaseUlcerative Colitis
CompletedInterventional · Phase 3NCT03345836 ↗A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic TherapyAliza B SolomonPIInterventionDrug: Matching Placebo for Upadacitinib · Drug: UpadacitinibDatesNov 2017 – Aug 2021· Results postedSponsorAbbVie Inc.Crohn's Disease
CompletedInterventional · Phase 3NCT03364491 ↗Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled TrialDaniel W SkupskiPIInterventionDrug: Tranexamic Acid · Drug: PlaceboDatesMar 2018 – Jul 2021· Results postedSponsorEunice Kennedy Shriver National Institute of Child Health and Human DevelopObstetrical ComplicationsHemorrhageLabor and Delivery
CompletedInterventional · Phase 3NCT03377491 ↗Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic AdenocarcinomaHiginia CardenesPIInterventionDevice: NovoTTF-200T · Drug: Gemcitabine · Drug: nab paclitaxelDatesMay 2018 – Oct 2024· Results postedSponsorNovocure, Ltd.Pancreas Adenocarcinoma
CompletedInterventional · Phase 3NCT03587116 ↗AN OPEN-LABEL, NON-INVESTIGATIONAL PRODUCT, LEAD-IN STUDY TO EVALUATE AT LEAST 6 MONTHS OF PROSPECTIVE EFFICACY AND SAFETY DATA OF FACTOR IX OR FACTOR VIII PROPHYLAXIS REPLACEMENT THERAPY IN THE USUAL CARE SETTING OF MODERATELY SEVERE TO SEVERE ADULT HEMOPHILIA B SUBJECTS (FIX:C≤2%) WHO ARE NEGATIVE FOR nAb TO AAV VECTOR-SPARK100 AND MODERATELY SEVERE TO SEVERE HEMOPHILIA A ADULT SUBJECTS (FVIII:C≤1%) WHO ARE NEGATIVE FOR nAb TO AAV VECTOR SB-525 CAPSID (AAV6), PRIOR TO THE RESPECTIVE THERAPEUTIC PH 3 GENE THERAPY STUDIES (See Detailed Description Section for Official Protocol Title)Catherine McGuinnPIInterventionDrug: Standard of Care FIX Replacement therapy · Drug: Standard of Care FVIII Replacement therapyDatesJul 2018 – Dec 2024· Results postedSponsorPfizer, Inc.Hemophilia BHemophilia A
CompletedInterventional · Phase 3NCT03607838 ↗A Multicenter, Randomized, Double-blind, Sham-controlled, Comparative Study of SI-6603 in Subjects With Lumbar Disc Herniation (Phase 3)Jason HuPIInterventionDrug: SI-6603 · Drug: Sham injectionDatesNov 2018 – Aug 2022· Results postedSponsorSeikagaku CorporationLumbar Disc Herniation
CompletedInterventional · Phase 3NCT03619213 ↗An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)Parag GoyalPIInterventionDrug: Dapagliflozin · Drug: PlaceboDatesAug 2018 – Mar 2022· Results postedSponsorAstraZeneca Pharmaceuticals LPHeart Failure With Preserved Ejection Fraction
CompletedInterventional · Phase 3NCT03626688 ↗A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAHEvelyn M. HornPIInterventionDrug: Ralinepag · Drug: PlaceboDatesJan 2019 – Dec 2025SponsorUnited TherapeuticsPAHPulmonary HypertensionPulmonary Arterial Hypertension+8 more
CompletedInterventional · Phase 3NCT03635788 ↗A Phase III Study to Evaluate Long-Acting Antiretroviral Therapy in Non-Adherent HIV-Infected IndividualsMarshall J. GlesbyPIInterventionDrug: Standard of Care (SOC) Oral ART · Drug: Oral RPV · Drug: Oral CAB · Drug: RPV-LA Loading Dose · Drug: CAB-LA Loading Dose · Drug: RPV-LA Maintenance Dose · Drug: CAB-LA Maintenance DoseDatesMar 2019 – Feb 2024· Results postedSponsorNational Institute of Allergy & Infectious DiseasesHIV Infections
CompletedInterventional · Phase 3NCT03651128 ↗A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)Roger N PearsePIInterventionBiological: bb2121 · Drug: Daratumumab · Drug: Pomalidomide · Drug: Dexamethasone · Drug: Bortezomib · Drug: Ixazomib · Drug: Lenalidomide · Drug: Carfilzomib · Drug: ElotuzumabDatesApr 2019 – Apr 2026SponsorCelgene CorporationMultiple Myeloma
CompletedInterventional · Phase 3NCT03657160 ↗A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell TransplantationSebastian A. MayerPIInterventionDrug: Vedolizumab Placebo · Drug: VedolizumabDatesFeb 2019 – Feb 2022· Results postedSponsorMillennium Pharmaceuticals, Inc.Hematopoietic Stem Cells
CompletedInterventional · Phase 3NCT03734029 ↗A Phase 3, Multicenter, Randomized, Open-label, Active Controlled Trial of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice for HER2-low, Unresectable and/or Metastatic Breast Cancer SubjectsEleni AndreopoulouPIInterventionDrug: Trastuzumab deruxtecan (DS-8201a) · Drug: Capecitabine · Drug: Eribulin · Drug: Gemcitabine · Drug: Paclitaxel · Drug: Nab-paclitaxelDatesDec 2018 – Jan 2022· Results postedSponsorDaiichi Sankyo, Inc.Breast Cancer
CompletedInterventional · Phase 3NCT03745716 ↗A Phase III Multicenter, Randomized, Open Label Study of APR-246 in Combination With Azacitidine Versus Azacitidine Alone for the Treatment of (Tumor Protein) TP53 Mutant Myelodysplastic SyndromesGail J RobozPIInterventionDrug: APR-246 + azacitidine · Drug: AzacitidineDatesJan 2019 – Nov 2020· Results postedSponsorAprea Therapeutics ABMDS
CompletedInterventional · Phase 3NCT03764293 ↗A Randomized, Open-Label, International, Multi-Center, Phase 3 Clinical Study of PD-1 Antibody SHR-1210 Plus Apatinib Mesylate Versus Sorafenib as First-Line Therapy in Patients With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic TherapyElizabeta Cristina PopaPIInterventionDrug: SHR-1210 · Drug: Apatinib · Drug: SorafenibDatesJun 2019 – Feb 2022· Results postedSponsorJiangsu Hengrui Medicine Co., Ltd.Locally Advanced or Metastatic and Unresectable HCC
CompletedInterventional · Phase 3NCT03768414 ↗A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract CancersManish A ShahPIInterventionDrug: Cisplatin · Drug: Gemcitabine Hydrochloride · Drug: Nab-paclitaxelDatesFeb 2019 – Oct 2023· Results postedSponsorSouthwest Oncology GroupStage III Distal Bile Duct Cancer AJCC v8Stage III Gallbladder Cancer AJCC v8Stage III Intrahepatic Cholangiocarcinoma AJCC v8+14 more